Abstract

ObjectivesThe objectives of this study are to examine the long-term efficacy and adverse effects of adjuvant radiotherapy (RT) for stage I testicular seminoma. Methods and materialsA retrospective review was conducted in 199 patients with stage I testicular seminoma treated with curative intent orchiectomy and adjuvant megavoltage RT at the institution from January 1, 1972 through December 31, 2009. Computed tomography staging was performed for 90% of the patients. No patient received mediastinal RT or adjuvant chemotherapy. Overall survival (OS), cause-specific survival, relapse rate, major cardiac event (MCE), and second malignancy (SM) were estimated using the Kaplan-Meier method. ResultsThe median age of the patients was 36 years (range: 18–80). The nodal regions irradiated were the para-aortic and ipsilateral pelvic nodes in 147 patients (74%), the para-aortic nodes alone in 34 (17%), and the para-aortic and bilateral pelvic nodes in 18 (9%). The median RT dose was 25.5Gy (interquartile range: 25–30). The median follow-up after RT was 13 years (range: 0.1–37). OS at 10 and 20 years was 92% and 77%, respectively. Cause-specific survival at 10 and 20 years was both 99%. Risk of relapse at 10 and 20 years was 1% and 2%, respectively. Risks of MCE and SM at 20 years were 12% and 19%, respectively. ConclusionsThis series confirms an excellent outcome in patients with stage I testicular seminoma treated with RT. Relapse after adjuvant RT is very uncommon, but late morbidity associated with RT may occur.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call